These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 24880663)

  • 81. Localized scleroderma: clinical spectrum and therapeutic update.
    Careta MF; Romiti R
    An Bras Dermatol; 2015; 90(1):62-73. PubMed ID: 25672301
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Early morphea simulating patch-stage mycosis fungoides.
    Fujimoto M; Basko-Plluska JL; Petronic-Rosic V; Shea CR
    Am J Dermatopathol; 2015 May; 37(5):409-12. PubMed ID: 25768945
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Morphea and localized scleroderma in children.
    Vierra E; Cunningham BB
    Semin Cutan Med Surg; 1999 Sep; 18(3):210-25. PubMed ID: 10468041
    [TBL] [Abstract][Full Text] [Related]  

  • 84. The isomorphic response in morphealike chronic graft-vs-host disease.
    Patel AR; Pavletic SZ; Turner ML; Cowen EW
    Arch Dermatol; 2008 Sep; 144(9):1229-31. PubMed ID: 18794477
    [No Abstract]   [Full Text] [Related]  

  • 85. [Morphea associated with toxoplasmosis].
    Solovăstru L; Amălinei C
    Rev Med Chir Soc Med Nat Iasi; 2003; 107(3):646-9. PubMed ID: 14756079
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Immunologic underpinnings and treatment of morphea.
    LaChance AH; Goldman N; Kassamali B; Vleugels RA
    Expert Rev Clin Immunol; 2022 May; 18(5):461-483. PubMed ID: 35403538
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Superficial morphea: case report, look-alikes, pathogenesis, and treatment.
    Loyal J; Norris II; Lester EB; Pierson JC
    Dermatol Online J; 2017 May; 23(5):. PubMed ID: 28537856
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Successful treatment with baricitinib of linear morphea following the lines of Blaschko mimicking lichen striatus.
    Zou Q; Wei R; Yao Z; Li H
    J Dermatol; 2024 Jan; 51(1):115-119. PubMed ID: 37830382
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Nodular morphea.
    Kauer F; Simon JC; Sticherling M
    Dermatology; 2009; 218(1):63-6. PubMed ID: 19005241
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Clinicohistopathological correlations in juvenile localized scleroderma: studies on a subset of children with hypopigmented juvenile localized scleroderma due to loss of epidermal melanocytes.
    Sung JJ; Chen TS; Gilliam AC; McCalmont TH; Gilliam AE
    J Am Acad Dermatol; 2011 Aug; 65(2):364-373. PubMed ID: 21570153
    [TBL] [Abstract][Full Text] [Related]  

  • 91. A systematic review of morphea treatments and therapeutic algorithm.
    Zwischenberger BA; Jacobe HT
    J Am Acad Dermatol; 2011 Nov; 65(5):925-41. PubMed ID: 21645943
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Case study: periodic follow-up is necessary in morphea profunda to identify systemic evolution.
    Melani L; Cardinali C; Giomi B; Schincaglia E; Caproni M; Fabbri P
    Skinmed; 2005; 4(3):188-90. PubMed ID: 15891259
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Circumscribed scleroderma induced by postlumpectomy radiation therapy.
    Trattner A; Figer A; David M; Lurie H; Sandbank M
    Cancer; 1991 Nov; 68(10):2131-3. PubMed ID: 1655201
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Assessment of esophageal involvement in systemic sclerosis and morphea (localized scleroderma) by clinical, endoscopic, manometric and pH metric features: a prospective comparative hospital based study.
    Arif T; Masood Q; Singh J; Hassan I
    BMC Gastroenterol; 2015 Feb; 15():24. PubMed ID: 25888470
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Type 1 IFN-induced protein MxA and plasmacytoid dendritic cells in lesions of morphea.
    Ghoreishi M; Vera Kellet C; Dutz JP
    Exp Dermatol; 2012 Jun; 21(6):417-9. PubMed ID: 22507598
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Tick Bite-Associated Morphea: A Case Report.
    George E; Nielson CB; Vincek V
    Am J Dermatopathol; 2019 Oct; 41(10):747-749. PubMed ID: 30325752
    [TBL] [Abstract][Full Text] [Related]  

  • 97. [Systemic sclerosis and scleroderma circumscripta--disturbances of selected serum parameters which are responsible for vascular changes and CD34 expression in involved skin].
    Dziankowska-Bartkowiak B; Zebrowska A; Wagrowska-Danielewicz M; Kobos J; Waszczykowska E
    Przegl Lek; 2009; 66(12):1040-5. PubMed ID: 20514902
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Localization of sclerotic-type chronic graft-vs-host disease to sites of skin injury: potential insight into the mechanism of isomorphic and isotopic responses.
    Martires KJ; Baird K; Citrin DE; Hakim FT; Pavletic SZ; Cowen EW
    Arch Dermatol; 2011 Sep; 147(9):1081-6. PubMed ID: 21931046
    [TBL] [Abstract][Full Text] [Related]  

  • 99. A case of radiation-induced generalized morphea with prominent mucin deposition and tenderness.
    Yanaba K; Umezawa Y; Nakagawa H
    Am J Case Rep; 2015 May; 16():279-82. PubMed ID: 25958415
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Recent Advances in Treatment of Systemic Sclerosis and Morphea.
    Teske N; Fett N
    Am J Clin Dermatol; 2024 Mar; 25(2):213-226. PubMed ID: 38087156
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.